JP2023514324A5 - - Google Patents
Info
- Publication number
- JP2023514324A5 JP2023514324A5 JP2022549457A JP2022549457A JP2023514324A5 JP 2023514324 A5 JP2023514324 A5 JP 2023514324A5 JP 2022549457 A JP2022549457 A JP 2022549457A JP 2022549457 A JP2022549457 A JP 2022549457A JP 2023514324 A5 JP2023514324 A5 JP 2023514324A5
- Authority
- JP
- Japan
- Prior art keywords
- nanocarrier
- prodrug
- lipid
- item
- formulated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025204012A JP2026032152A (ja) | 2020-02-19 | 2025-11-26 | がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062995887P | 2020-02-19 | 2020-02-19 | |
| US62/995,887 | 2020-02-19 | ||
| PCT/US2021/010005 WO2021167703A1 (en) | 2020-02-19 | 2021-02-19 | Formulated and/or co-formulated liposome compositions containing tgfb antagonist prodrugs useful in the treatment of cancer and methods thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025204012A Division JP2026032152A (ja) | 2020-02-19 | 2025-11-26 | がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023514324A JP2023514324A (ja) | 2023-04-05 |
| JP2023514324A5 true JP2023514324A5 (cg-RX-API-DMAC7.html) | 2024-02-27 |
| JP7842690B2 JP7842690B2 (ja) | 2026-04-08 |
Family
ID=75223393
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022549457A Active JP7842690B2 (ja) | 2020-02-19 | 2021-02-19 | がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法 |
| JP2025204012A Pending JP2026032152A (ja) | 2020-02-19 | 2025-11-26 | がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025204012A Pending JP2026032152A (ja) | 2020-02-19 | 2025-11-26 | がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US11801304B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4096716A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7842690B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20220143063A (cg-RX-API-DMAC7.html) |
| CN (3) | CN121287708A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2021223336B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3170142A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021167703A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7842690B2 (ja) * | 2020-02-19 | 2026-04-08 | ナミ セラピューティクス, インコーポレイテッド | がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法 |
| CN112669958B (zh) * | 2020-12-08 | 2022-09-09 | 河北医科大学第二医院 | 代谢物作为疾病诊断的生物标志物 |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1539748A1 (en) * | 2002-07-31 | 2005-06-15 | Smithkline Beecham Corporation | 2-phenylpyridin-4-yl derivatives as alk5 inhibitors |
| UA80571C2 (en) | 2002-11-22 | 2007-10-10 | Lilly Co Eli | Quinolinyl-pyrrolopyrazoles |
| US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
| BRPI0506629A (pt) | 2004-02-10 | 2007-05-02 | Univ Colorado | inibição do fator b, a via alternativa do sistema complemento e métodos relacionados |
| WO2006031471A2 (en) | 2004-09-01 | 2006-03-23 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Liposomal vectors |
| US7795389B2 (en) | 2004-09-28 | 2010-09-14 | The Board Of Regents Of The University Of Texas System | Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins |
| CA2632799A1 (en) | 2005-12-23 | 2007-07-05 | Eli Lilly And Company | Tgf-beta binding compositions |
| JP5951254B2 (ja) | 2008-03-17 | 2016-07-13 | ザ スクリプス リサーチ インスティテュート | 人工多能性幹細胞を作製するための化学的手法と遺伝的手法の組み合わせ法 |
| PT104158B (pt) | 2008-08-18 | 2011-02-24 | Univ Do Minho | Aplicação da monooleína como novo lípido adjuvante em lipofecção |
| MX389666B (es) | 2009-10-16 | 2025-03-19 | Scripps Research Inst | Induccion de celulas pluripotentes. |
| US20130189780A1 (en) | 2009-12-31 | 2013-07-25 | Fate Therapeutics, Inc. | Reprogramming compositions |
| US8080568B1 (en) | 2010-06-29 | 2011-12-20 | Ewha University - Industry Collaboration Foundation | 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors |
| US8871744B2 (en) * | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
| EP2714735B1 (en) | 2011-06-03 | 2021-07-21 | XOMA Technology Ltd. | Antibodies specific for tgf-beta |
| CN103857384B (zh) | 2011-06-06 | 2017-07-11 | 大学健康网络 | 用于合成卟啉‑磷脂结合物的方法 |
| CN104023749B (zh) | 2011-09-14 | 2019-12-17 | 西北大学 | 能穿过血脑屏障的纳米缀合物 |
| US9782452B2 (en) | 2011-11-22 | 2017-10-10 | Cornell University | Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling |
| US8871189B2 (en) * | 2011-11-30 | 2014-10-28 | Mallinckrodt Llc | MMP-targeted therapeutic and/or diagnostic nanocarriers |
| CA2874490C (en) * | 2012-05-23 | 2021-11-16 | The Ohio State University | Tertiary quaternary amine-based cationic lipid nanoparticle compositions and methods of making and methods of using the same |
| HRP20201914T1 (hr) | 2013-05-06 | 2021-01-22 | Scholar Rock, Inc. | Sastavi i postupci za modulaciju faktora rasta |
| AU2014278178B2 (en) | 2013-06-11 | 2021-01-21 | President And Fellows Of Harvard College | SC-beta cells and compositions and methods for generating the same |
| PL3137473T3 (pl) | 2014-05-02 | 2020-06-01 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Pochodne Pt (iv) i zawierające je nanonośniki |
| CN107073042A (zh) | 2014-09-03 | 2017-08-18 | 布里格海姆妇女医院公司 | 用于产生内耳毛细胞来治疗听力损失的组合物、系统和方法 |
| WO2016123573A1 (en) | 2015-01-30 | 2016-08-04 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
| WO2016149756A1 (en) * | 2015-03-23 | 2016-09-29 | The University Of Melbourne | Treatment of respiratory diseases |
| JP6602847B2 (ja) * | 2015-03-27 | 2019-11-06 | 株式会社ボナック | デリバリー機能と遺伝子発現制御能を有する一本鎖核酸分子 |
| WO2018081480A1 (en) * | 2016-10-26 | 2018-05-03 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| AU2017210031C1 (en) | 2016-01-20 | 2020-11-26 | Fate Therapeutics, Inc. | Compositions and methods for immune cell modulation in adoptive immunotherapies |
| CN106176609B (zh) * | 2016-08-22 | 2019-10-15 | 南通大学 | 一种nk细胞膜仿生脂质体药物载体、制作方法及其应用 |
| IL268995B2 (en) | 2017-03-02 | 2024-02-01 | Nat Res Council Canada | TGF-B receptor ectodomain fusion compounds and their uses |
| GB201707561D0 (en) | 2017-05-11 | 2017-06-28 | Argenx Bvba | GARP-TGF-beta antibodies |
| US11433143B2 (en) | 2017-05-18 | 2022-09-06 | The Regents Of The University Of California | Nano-enabled immunotherapy in cancer |
| CA3063932A1 (en) | 2017-05-18 | 2018-11-12 | The Regents Of The University Of California | Nano-enabled immunotherapy in cancer |
| US11046729B2 (en) | 2017-10-26 | 2021-06-29 | Southern Research Institute | Dipeptide analogs as TGF-beta inhibitors |
| AU2018431586B2 (en) | 2018-07-09 | 2025-03-20 | Synthis Therapeutics, Inc | Antibody-ALK5 inhibitor conjugates and their uses |
| US12448475B2 (en) * | 2019-06-21 | 2025-10-21 | The University Of North Carolina At Chapel Hill | Drug delivery compositions and applications thereof |
| JP7842690B2 (ja) * | 2020-02-19 | 2026-04-08 | ナミ セラピューティクス, インコーポレイテッド | がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法 |
-
2021
- 2021-02-19 JP JP2022549457A patent/JP7842690B2/ja active Active
- 2021-02-19 AU AU2021223336A patent/AU2021223336B2/en active Active
- 2021-02-19 KR KR1020227031715A patent/KR20220143063A/ko active Pending
- 2021-02-19 CA CA3170142A patent/CA3170142A1/en active Pending
- 2021-02-19 CN CN202511406387.5A patent/CN121287708A/zh active Pending
- 2021-02-19 US US17/300,063 patent/US11801304B2/en active Active
- 2021-02-19 WO PCT/US2021/010005 patent/WO2021167703A1/en not_active Ceased
- 2021-02-19 EP EP21714458.3A patent/EP4096716A1/en active Pending
- 2021-02-19 CN CN202180019109.8A patent/CN115243724B/zh active Active
-
2023
- 2023-07-10 US US18/445,323 patent/US20240050575A1/en active Pending
-
2024
- 2024-05-13 KR KR1020267003654A patent/KR20260035240A/ko active Pending
- 2024-05-13 US US18/831,041 patent/US20250032620A1/en active Pending
- 2024-05-13 EP EP24733354.5A patent/EP4743119A1/en active Pending
- 2024-05-13 AU AU2024339588A patent/AU2024339588A1/en active Pending
- 2024-05-13 CN CN202480045094.6A patent/CN121487753A/zh active Pending
-
2025
- 2025-11-26 JP JP2025204012A patent/JP2026032152A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113645960B (zh) | 含有氧化的胆固醇的药物递送系统 | |
| US20250195641A1 (en) | Immunotherapeutic constructs and methods of their use | |
| US12059500B2 (en) | Therapeutic constructs for co-delivery of mitotic kinase inhibitor and immune checkpoint inhibitor | |
| JP6427097B2 (ja) | 癌を処置するための組成物および該組成物を製造するための方法 | |
| CN116133652A (zh) | 制备脂质纳米粒子的方法 | |
| JP7566629B2 (ja) | ランゲリン+細胞ターゲティング | |
| JP2024515650A5 (cg-RX-API-DMAC7.html) | ||
| EP3442542B1 (en) | Nanoparticles, controlled-release dosage forms, and methods for delivering an immunotherapeutic agent | |
| JP7561146B2 (ja) | 接着している粒子を有する赤血球に関連する組成物および方法 | |
| KR20230004563A (ko) | 강력한 암 면역치료제로서 리포좀성 구형 핵산 내 캡슐화된 산화된 종양 세포 용해물 | |
| US20190298824A1 (en) | Albumin-binding immunomodulatory compositions and methods of use thereof | |
| US20210177871A1 (en) | Methods for cancer therapy | |
| JP2023502182A5 (cg-RX-API-DMAC7.html) | ||
| CN118215496A (zh) | 抗原和药物-脂质缀合物的免疫调节组合 | |
| EP3536343A1 (en) | Skin fibrosis treatment agent | |
| US20240376479A1 (en) | Aptamers for targeted activation of t cell-mediated immunity | |
| KR20240102993A (ko) | 암의 면역요법 치료를 위한 cGAS-STING 및 STAT3 경로 조절용 구형 핵산 | |
| US20240417738A1 (en) | Immunotherapies for the treatment of cancer | |
| JP2026035730A (ja) | 免疫療法構築物およびその使用方法 |